Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRIW) EPS (Weighted Average and Diluted) (2021 - 2025)

Biofrontera has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at $0.63 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.63 for Q4 2025, up 270.59% from a year ago — trailing twelve months through Dec 2025 was -$1.03 (up 72.46% YoY), and the annual figure for FY2025 was -$1.04, up 67.7%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.63 at Biofrontera, up from -$0.62 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BFRIW hit a ceiling of $4.55 in Q4 2023 and a floor of -$7.23 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.57 (2025), compared with a mean of -$1.1.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 270.59% in 2025, while the deepest fall reached 1040.0% in 2025.
  • Biofrontera's EPS (Weighted Average and Diluted) stood at -$2.0 in 2021, then plummeted by 40.0% to -$2.8 in 2022, then skyrocketed by 262.5% to $4.55 in 2023, then plummeted by 96.26% to $0.17 in 2024, then surged by 270.59% to $0.63 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.63 (Q4 2025), -$0.62 (Q3 2025), and -$0.57 (Q2 2025) per Business Quant data.